Azione CYTOKINETICS, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati
Strumento inattivo

Altre lingue Cytokinetics, Inc. Nasdaq

Azioni

US23282W1009

Prezzo di chiusura Nasdaq
Altri mercati azionari
- USD - Grafico intraday di Cytokinetics, Inc.
15/05 Transcript : Cytokinetics, Incorporated - Shareholder/Analyst Call
13/05 Transcript : Cytokinetics, Incorporated - Special Call

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
Cytokinetics Q1 Net Loss Narrows, Revenue Declines
Cytokinetics: Q1 Earnings Snapshot
Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Posts Q1 Revenue $835,000, vs. Street Est of $0.9M
Cytokinetics Reports First Quarter 2024 Financial Results
Cytokinetics, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586
Cytokinetics, Incorporated Announces Topline Data from Phase 1 Clinical Study of Ck-4021586
Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment
Cytokinetics Insider Sold Shares Worth $1,012,265, According to a Recent SEC Filing
Cytokinetics to Hold Annual Meeting of Stockholders
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics Appoints Sung Lee as CFO
Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024
Cytokinetics, Incorporated Announces Chief Financial Officer Changes, Effective May 8, 2024
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione CYTK
  4. Azione
  5. Notizie Cytokinetics, Inc.
  6. Altre lingue